NLS Pharma Business

The agreement, building on a letter of intent announced earlier this year, is intended to establish a long-term partnership in spray-dried formulations, a technology considered important for the development of inhalable drug formulations for biologics, vaccines, and other large molecules.

Following the outcome of the DIAGNODE-3 study, the company’s immediate priority is to complete the close-out of the Phase 3 program in an efficient and responsible manner, it states.

Qlucore has received approval for a third payment of approximately EUR 0.5 million under its previously awarded EU grant. The total grant amounts to EUR 2.5 million and is distributed across four installments.

Immunovia has announced new performance data for PancreaSure in support of its upcoming Medicare coverage application.

Camurus has received a Complete Response Letter from the US Food and Drug Administration regarding its New Drug Application for CAM2029 (Oclaiz), a once-monthly octreotide treatment for patients with acromegaly.

The company is strengthening its focus on new partnerships through the appointment of Raheleh Nassaji as Senior Vice President Business Development.